Drug Comparison Hub

Estradiol vs Estriol

Estradiol is the strongest estrogen and FDA-approved standard for hormone therapy (transdermal patch, oral, vaginal ring). Estriol is a weaker estrogen used primarily for vaginal atrophy — only available via compounding pharmacies in the US.

Micronized progesterone vs Medroxyprogesterone

Micronized progesterone (Prometrium) is bioidentical and evidence-preferred. Medroxyprogesterone (Provera) is synthetic — associated with slightly higher breast cancer risk in WHI data.

Estradiol patch vs Estradiol gel

Both deliver bioidentical estradiol transdermally, avoiding first-pass liver metabolism and both lower VTE risk vs oral estradiol. Patches (Climara, Vivelle-Dot) apply once or twice weekly. Gels (EstroGel, Divigel) require daily application. Choice usually comes down to skin tolerance and lifestyle preference.

Bioidentical HRT vs Synthetic HRT

Bioidentical HRT (FDA-approved): estradiol patches/gels/pills + micronized progesterone (Prometrium) — molecularly identical to endogenous hormones. Synthetic HRT (historical): conjugated equine estrogens (Premarin) + medroxyprogesterone (Provera) — used in the original WHI trial. Modern guidelines favor FDA-approved bioidentical formulations.

Wegovy vs Zepbound

Wegovy (semaglutide) achieves 14-15% average body-weight loss at 68 weeks. Zepbound (tirzepatide) achieves 20-21% — Zepbound wins on efficacy. Costs similar ($1,000-1,350/mo retail). Side effects similar (mostly GI). Mounjaro and Ozempic contain the same molecules but are FDA-approved for diabetes rather than weight loss.

Mounjaro vs Ozempic

Both are FDA-approved for type 2 diabetes. Mounjaro (tirzepatide) lowers A1c more and produces more weight loss than Ozempic (semaglutide). Ozempic has longer real-world track record and broader insurance formulary coverage. Mounjaro has slightly more GI side effects in head-to-head trials (SURPASS-2).

Semaglutide vs Tirzepatide

Ingredient-level comparison. Semaglutide is a GLP-1 receptor agonist (single pathway). Tirzepatide is a dual GIP + GLP-1 receptor agonist. Tirzepatide produces ~6 percentage points more weight loss and slightly better A1c reduction in head-to-head trials. Both available as four FDA-approved brands (Ozempic/Wegovy = semaglutide; Mounjaro/Zepbound = tirzepatide).

Zepbound vs Ozempic

Zepbound (tirzepatide) is FDA-approved for chronic weight management — average 22.5% weight loss at highest dose (SURMOUNT-1). Ozempic (semaglutide) is FDA-approved for type 2 diabetes — about 15% weight loss when used off-label. Both injectable weekly, similar side-effect profiles.

Wegovy vs Ozempic

Wegovy and Ozempic contain the same active ingredient — semaglutide — made by Novo Nordisk. Wegovy is FDA-approved for chronic weight management (max 2.4 mg weekly). Ozempic is FDA-approved for type 2 diabetes (max 2 mg weekly). Different brand, different indication, same molecule.

Mounjaro vs Wegovy

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Wegovy (semaglutide) is FDA-approved for chronic weight management. Different mechanisms (dual GIP/GLP-1 vs single GLP-1), different indications. For diabetes Mounjaro typical; for weight loss Wegovy or Mounjaro's weight-loss sibling Zepbound.

Compounded semaglutide vs FDA-approved semaglutide

Compounded semaglutide is mixed by licensed compounding pharmacies, often with additives (B12, glycine) and at lower cash prices ($200-400/month). FDA-approved semaglutide (Ozempic, Wegovy) costs $935-1,349/month list but carries Novo Nordisk's quality, safety, and trial-data standards. FDA does not verify compounded products.

Paroxetine vs Escitalopram

Paroxetine 7.5mg (Brisdelle) is FDA-approved for hot flashes — 30-40% reduction. Escitalopram off-label but similar efficacy and often better tolerated.